Table 1 Background characteristics of respondents
n | (%) | ||
|---|---|---|---|
Sex | Male | 200 | (55.7) |
Female | 158 | (44.0) | |
No response | 1 | (0.3) | |
Pharmacy experience, years | 1 to 3 | 8 | (2.2) |
4 to 6 | 42 | (11.7) | |
7 to 9 | 44 | (12.3) | |
10 to 14 | 94 | (26.2) | |
15 to 19 | 65 | (18.1) | |
more than 19 | 105 | (29.2) | |
No response | 1 | (0.3) | |
Receives “Total drug evaluation and management healthcare reimbursement fee” | |||
Yes | 176 | (49.0) | |
No | 183 | (51.0) | |
Board pharmacy certification | Yes | 222 | (61.8) |
No | 130 | (36.2) | |
No response | 7 | (1.9) | |
BCPPP1) | 123 | (34.3) | |
BCPOP2) | 82 | (22.8) | |
JSPHCS3) certification of Oncology Pharmacist | 52 | (14.5) | |
APACC4) | 32 | (8.9) | |
Pharmacists with certifications other than BCPPP | 99 | (27.6) | |
Confidence score in palliative care (No confidence, 0; full confidence, 10) | |||
Zero | 5 | (1.4) | |
1 | 7 | (1.9) | |
2 | 5 | (1.4) | |
3 | 9 | (2.5) | |
4 | 10 | (2.8) | |
5 | 54 | (15.0) | |
6 | 76 | (21.2) | |
7 | 92 | (25.6) | |
8 | 69 | (19.2) | |
9 | 24 | (6.7) | |
10 | 8 | (2.2) | |
Nationwide attendance at continuing education sessions related to palliative care in a year | |||
Zero | 17 | (4.7) | |
1 to 3 | 260 | (72.4) | |
4 to 6 | 58 | (16.2) | |
7 to 9 | 14 | (3.9) | |
More than 9 | 10 | (2.8) | |
Percentage of cancer patients managed by pharmacists | |||
Zero | 7 | (1.9) | |
1 to 39% | 97 | (27.0) | |
40 to 69% | 94 | (26.2) | |
70 to 99% | 103 | (28.7) | |
100% | 58 | (16.2) | |